Eija Rosenblad

Learn More
This phase 2 study evaluated the safety and efficacy of alemtuzumab in 22 patients with advanced mycosis fungoides/Sézary syndrome (MF/SS). Most patients had stage III or IV disease, reduced performance status, and severe itching. The overall response (OR) rate was 55%, with 32% of patients in complete remission (CR) and 23% in partial remission (PR).(More)
For the evaluation of clothing by human beings, two different approaches can be identified--laboratory tests (i.e. climatic chamber tests) or field trials/wear trials. It has been suggested that the performance of clothing can be adequately predicted on the basis of the data obtained from climatic chamber tests and that field trials may be expendable(More)
  • 1